Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bruton tyrosine kinase inhibitors

12 evidence topics · 8 sources

REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information
Outcome at Week 12REMIX-1 remibrutinib (N = 309)REMIX-1 placebo (N = 153)REMIX-2 remibrutinib (N = 297)REMIX-2 placebo (N = 153)
LS mean (SE) change in ISS7“-9.52 (0.34)”“-6.89 (0.47)”“-8.95 (0.34)”“-5.72 (0.45)”
LS mean (SE) change in HSS7“-10.47 (0.40)”“-6.86 (0.55)”“-10.47 (0.39)”“-6.00 (0.53)”
LS mean (SE) change in UAS7“-20.02 (0.72)”“-13.79 (0.98)”“-19.41 (0.70)”“-11.73 (0.95)”
UAS7 ≤6, n (%)“154 (49.8)”“38 (24.8)”“139 (46.8)”“30 (19.6)”
UAS7 = 0, n (%)“96 (31.1)”“16 (10.5)”“83 (27.9)”“10 (6.5)”
Treatment difference versus placebo at Week 12REMIX-1REMIX-2
UAS7 difference in LS mean (SE)“-6.22 (1.14)”“-7.68 (1.14)”
UAS7 95% CI for difference“-8.45, -4.00”“-9.91, -5.46”
UAS7 ≤6 treatment difference (95% CI)“25.44”“16.48, 34.39”“27.61”“19.14, 36.08”
UAS7 = 0 treatment difference (95% CI)“20.55”“13.35, 27.75”“21.60”“15.10, 28.10”
REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events

“A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Funded by Novartis Pharmaceuticals;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52

“To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders
Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU

“What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary analysis population included only the 143 omalizumab-naive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P  = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P  = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Further research is needed to determine long-term efficacy and potential harms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote